Key clinical point: Adding a CD38-targeted monoclonal antibody improves outcomes for patients with relapsed/refractory multiple myeloma.
Major finding: The hazard ratio for progression free survival with the combo, Isa-Kd, was 0.531.
Study details: Randomized trial in 302 patients with multiple myeloma relapsed or refractory after one to three prior lines of therapy.
Disclosures: The study was sponsored by Sanofi. Dr. Moreau disclosed honoraria and a consulting or advisory role with several companies, not including Sanofi.
Moreau P et al. EHA Congress, Abstract LB2603.